Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 4, 2010, Pages 807-812

  Zaremba, Tomasz ^a,b   Thomas, Huw ^a   Cole, Michael ^a   Plummer, Elizabeth R ^a   Curtin, Nicola J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Doxorubicin; Monozygotic twins; PARP inhibitors; PARP 1; PARP 1 activity; PARP 1 expression

Indexed keywords

8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; DOXORUBICIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN;

AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CASE REPORT; CLINICAL STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; HUMAN; MALE; MONOZYGOTIC TWINS; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; METABOLISM; MUSCLE TUMOR; PATHOLOGY; SARCOMA; TWINS; CLINICAL TRIAL (TOPIC); HUMAN CELL; PHARMACOGENETICS;

AGED; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; DOXORUBICIN; ENZYME INHIBITORS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MUSCLE NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; SARCOMA; TWINS, MONOZYGOTIC;

ANIMALIA; MUS;

EID: 78149294004     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1359-0     Document Type: Article

References (14)

1. Boomsma D, Busjahn A, Peltonen L (2002) Classical twin studies and beyond. Nat Genet 3:872-882
2. Ring HZ, Valdes AM, Nishita DM, Prasad S, Jacob P, Tyndale RF, Swan GE, Benowitz NL (2007) Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. Pharmacogenet Genomics 17:1007-1015
3. Pedersen NL, Lichtenstein P, Svedberg P (2002) The Swedish Twin Registry in the third millennium. Twin Res 5:427-432
4. Cormier NJ, Pollock RE (2004) Soft tissue sarcomas. CA Cancer J Clin 54:94-109
5. Demetri GD (1998) Major developments in the understanding and treatment of soft tissue sarcomas in adults. Curr Opin Oncol 10:343-347
6. Curtin NJ (2005) PARP inhibitors for cancer therapy. Expert Rev Mol Med 15:1-20
7. Mason KA, Valdecanas D, Hunter NR, Milas L (2008) INO-1001, a novel inhibitor of poly (ADP-ribose) polymerase, enhances tumor response to doxorubicin. Invest New Drugs 26:1-5
8. Plummer ER, Middleton MR, Jones C et al (2005) Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O-6-alkylguanine alkyltransferase and poly (ADP-ribose) polymerase-1. Clin Cancer Res 11:3402-3409
9. Plummer R, Jones C, Middleton M, Wilson R et al (2008) Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 14:7917-7923
10. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685
11. Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, Hasko G, Szabo C (2002) Activation of poly (ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 300:862-867
12. Ranjit GB, Cheng MF, Mackay W et al (1995) Poly (adenosine diphosphoribose) polymerase in peripheral blood leukocytes from normal donors and patients with malignancies. Clin Cancer Res 1:223-234
13. Mackall CL, Fleisher TA, Brown MR et al (1994) Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 84:2221-2228
14. Hakim FT, Cepeda R, Kaimei S et al (1997) Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 90:3789-3798